Enanta Pharmaceuticals Inc (ENTA) Quote

Media recognition & coverage -

Pharmaceutical Technology -
April 22

Enanta Pharmaceuticals gets grant for inhibiting coronavirus replication with compound of formula
Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Formula (I) represents the compound structure.

Excerpts:
Human telomerase RT biomarker was a key innovation area identified from patents.

The patent also covers pharmaceutical compositions containing the compound and a method for treating or preventing coronavirus infections in subjects by administering the compound or a combination of compounds.

....the patent involves administering a therapeutically effective amount of the compound to subjects in need, with specific mention of various types of coronaviruses, including SARS-CoV-2. This patent highlights the potential use of the disclosed compounds in combating coronavirus infections, particularly relevant in the current global health scenario.

https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-inhibiting-coronavirus-replication-with-compound-of-formula-i-2/?utm_source=lgp6-patents-grant&utm_medium=24-295866&utm_campaign=recommended-articles-pi&cf-view

I never considered a data leak on the RSV drug, but there could be a leak on ensitrelvir data (run by NIH and they have data in hand so could be more leaky than if was strictly managed by shionogi I think) or some happenings in the court case. Most likely of course is that the recent drop is just due to inherent volatility

Right! ENTA updated the guidance for RSVHR reporting on the Leerink webcast on 3/13/24 (the same date as the “new” corporate slide set). The prior “it depends” guidance was from ENTA’s FY1Q24 CC on 2/7/24.

In any event, the salient point is that ENTA is not due to report any clinical data until July at the earliest. This should reassure anyone who may have thought the recent share-price decline was due to a data leak.

ENTA has not yet commented on when it will report data from the Zelicapavir PSVHR trial (for high-risk adults) because that depends on whether enrollment is completed during the current RSV season in the Northern Hemisphere.

ENTA mentioned that they will have to go to the southern hemisphere for the RSVHR study so enrollment won't be completed for this study in the 2024 northern hemisphere season, but could still be completed this calendar year after the southern hemisphere season
I don't recall if ENTA had as much detail on the CSU program, but they did mention during the last presentation they have been working on it for a long time (over a year), so I am hoping they are not too far behind THRD (which incidentally has a higher valuation w their CSU program being the lone asset and cash through 2026 vs 2027 for ENTA)

ENTA corporate slide set (3/13/24):

https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

There are no differences between the 3/13/24 slide set and the previous slide set on 2/7/24.

Clinical newsflow reiteration: ENTA expects to report data from the Zelicapavir RSVPEDs trial and the EDP-938 “challenge” trial in 3Q24. ENTA has not yet commented on when it will report data from the Zelicapavir PSVHR trial (for high-risk adults) because that depends on whether enrollment is completed during the current RSV season in the Northern Hemisphere.

Just calling it the way I see it - ENTA does have a potential stake in paxlovid
PFE has been totally silent on their next gen PI for covid - the phase 2 was completed months ago

https://clinicaltrials.gov/study/NCT05799495?term=PF-07817883&rank=5

Regardless negative ensitrelvir data would still be bullish for ENTA because it is bullish for paxlovid which would make any potential settlement in the lawsuit more valuable (and vice versa of course if the ensitrelvir data are good)

I like the way you talk! 😂

The market is upset they are allocating the cost of a plane ticket to Spain and hotel for the presentation. It's a few thousand added burn ;)
Joking aside nice to see the data will be presented - it's the right thing to do even on what seems to be a defunct asset
235 could be revived if ensitrelvir doesn't post positive phase 3 data this month. Regardless negative ensitrelvir data would still be bullish for ENTA because it is bullish for paxlovid which would make any potential settlement in the lawsuit more valuable (and vice versa of course if the ensitrelvir data are good)

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Apr 17, 2024

No wonder ENTA dropped yesterday and today. It is a reminder that EDP-235 still hasn't moved into phase 3 despite excellent data in phase 2, either via partnership or funded by ENTA.

Capisce?

Everything makes CENTS in a potential takeover. I consider the patent holdings are worth their minimal expense - I.E. the patent infringement suit against PFIZER - if it pans out.

Legal Fees for Patent Applications and Patent Defense
The 8-K shows that patent defense legal fees are assigned to General and Administrative Expenses. Are patent application fees assigned to research and development costs? For years I thought Enanta's patent portfolio was a wonderful asset, but now I am wondering if it was an unscrupulous waste of money transferring oodles of cash from Enanta to their legal counsel. Kickback and enjoy. Capisce?

Patent Assigned to Enanta Pharmaceuticals, Inc.

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Type: Grant
Filed: May 19, 2021
Date of Patent: April 16, 2024

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

In certain embodiments, the FXR-mediated disease or condition is cardiovascular disease, atherosclerosis, arteriosclerosis, hypercholesteremia, or hyperlipidemia chronic liver disease, gastrointestinal disease, renal disease, metabolic disease, cancer (i.e., colorectal cancer), or neurological indications such as stroke.

https://patents.justia.com/patent/11958879

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Apr 17, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”
Abstract Number: 02980
Poster Number: PO423
Day: April 27, 2024
Time: 12:00 p.m. CEST / 6:00 a.m. ET
Session Location: Poster Area
Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)
Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.

The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-data-presentation-escmid-global

one must be able to describe the thinking and process one takes to create that molecule- if one is to defend their IP.

Thanks for your comments re:patents. Seems ENTA is flush with patents protecting their small molecule discoveries. It would make "cents" to have their discoveries certified & protected by their string of patent attorneys. **Pfizer - watch out!

**

I rather enjoy the updates on Enanta's being issued patents.
I long for the day that these will mean something palpable in it's share price.

I hold (or is it merely wishful thinking?) that a company that is centered on discovering molecules MUST have a branch that can rigorously defend those patents, that's skilled at filing patents. It isn't enough to merely create them after, one must be able to describe the thinking and process one takes to create that molecule- if one is to defend their IP.

I say this as Enanta's lawsuit progresses with Pfizer and hope that they have done the work required to successfully defend their IP.

They keep comin' !

Patents Assigned to Enanta Pharmaceuticals, Inc.
** Benzodiazepine derivatives as RSV inhibitors
Patent number: 11952389
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: May 3, 2022
Date of Patent: April 9, 2024

Patents Assigned to Enanta Pharmaceuticals, Inc.
Benzodiazepine derivatives as RSV inhibitors
Patent number: 11952389
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: May 3, 2022
Date of Patent: April 9, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
Assignee: Enanta Pharmaceuticals, Inc.

** What are Benzodiazepines? Benzodiazepines are depressants that produce sedation and hypnosis, relieve anxiety and muscle spasms, and reduce seizures. The most common benzodiazepines are the prescription drugs Valium®, Xanax®, Halcion®, Ativan®, and Klonopin®.

2 New Patents Assigned to Enanta Pharmaceuticals, Inc. as of April 2

Heterocyclic compounds as anti-viral agents
Patent number: 11945824
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: October 18, 2021
Date of Patent: April 2, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Yat Sun Or, Yong He, Kevin McGrath, Ruichao Shen, Adam Szymaniak, Xuechao Xing, In Jong Kim, Guoqiang Wang

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Addendum:

Taking account of the seasonality and predictability of the HRSV and HMPV epidemics, and the severity of infection in high-risk groups such as infants, immunocompromised patients and adults over the age of 65 years, the need for a potent and effective treatment for both HRSV and HMPV is clear. The present invention has identified heterocyclic compounds that are potent inhibitors of both HRSV-A/B and HMPV. The invention includes methods to prepare these compounds, methods for RSV/HMPV cell-based assays and methods of using these compounds to treat HRSV and/or HMPV infections.

https://patents.justia.com/patent/11945824

Antiviral heterocyclic compounds
Patent number: 11945830
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: February 24, 2022
Date of Patent: April 2, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Adam Szymaniak, Jianming Yu, Kevin McGrath, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Addendum:

The present invention has identified compounds that are heterocyclic molecules that are potent against HRSV-AB and HMPV. The invention includes methods to prepare these molecules, methods for the RSV cell-based assay, the HMPV-GFP cell-based assay, the HMPV-TN/1501/A1 cell-based assay, and small-molecules that have potential to treat HRSV/HMPV infection.

https://patents.justia.com/patent/11945830

What is heterocyclic used for?
Heterocyclic Compound - an overview | ScienceDirect Topics
The heterocyclic compounds play an important role in regulating the biochemical process in living system. The compounds may be genetic material, hormones, and enzymes. The common heterocyclic compounds that serve as potential leading drug candidates include amino acid, vitamins, and coenzymes.

https://endpts.com/loosening-medicaid-restrictions-on-hep-c-drugs-could-improve-patient-access-study-finds/

ENTA over $10

PHARMACEUTICAL TECHNOLOGY research news via GlobalData -

March 29, 2024
Enanta Pharmaceuticals gets grant for inhibiting coronavirus replication with compound of formula (i)

Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Claim 1 specifically pertains to a compound represented by Formula (I).

Excerpts:
Additionally, the patent includes claims for pharmaceutical compositions comprising the disclosed compound and methods for treating or preventing virus infections, specifically coronavirus infections such as those caused by 229E, NL63, OC43, HKU1, SARS-CoV, or MERS coronavirus.

The patent's claims highlight the compound's versatility in treating various virus infections and respiratory disorders, positioning it as a valuable asset in the field of antiviral and respiratory therapeutics.

Read more:
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-inhibiting-coronavirus-replication-with-compound-of-formula-i/

As impressive as this rise in ENTA stock price over this week (from $14 to $17.41), its market cap is still only $370 million. That means any solid positive news could drive a major price spike.

Not sure. Wish I have more money here than that damn RVNC. lol

I hesitate to post this but I'm going to include a link, a chart.
https://finviz.com/quote.ashx?t=ENTA&p=d
We've been in an uptrend and when I see a huge spike, or series of large spikes they are often followed by a selloff.
How well I know that lesson. : (

Maybe Enta will go up, and up.
BUT particularly if this is just a large day or a series of large days anyone just (or pondering) getting in should realize that someone is going to take profits.
IE, runups are often precursors to selloffs.

Since my broker had NO idea - I did some research to prevent my brokerage firm from "borrowing" my ENTA shares for any short sales.

How do I stop short sellers from borrowing my shares?
All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today's price. As they are 'on order' they cannot be lent out by your broker and in turn you are reducing the amount of 'free shares' out there that can be used for shorting purposes.

You aren't alone there.
I've been following and looking an a longer chart and it looked like a semi legit uptrend and so I bought in right at the top near $16.00 and it promptly went back to the basement. That must have been a few weeks ago.
I've got a knack that way. : )
Hey, IF I'm going to go down, I might as well go down in flames. : )
I'm feeling 10 percent smarter today but still in the red from last purchase.

What the heck is going on with ENTA today? Up more than 10% on no news. Could it be a leak about the lawsuit against PFE? Maybe not as the volume isn't particularly high.

As a new, approximately 6 month investor in ENTA, I appreciate the correction. Live & learn - thanks Dew

No. ENTA's lawsuit against PFE concerns protease inhibitors for SARS-CoV-2; it has nothing to with RSV.

Might the following new patent be valid for inclusion in the PFIZER suit?

COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS
File Date: .................... 2018-09-28.
Pub Date: .....................2024-03-20

Excerpts:

Background of the Invention:
RSV is the leading cause of acute lower respiratory tract infections (ALRI) and affects patients of all ages. The symptoms in adults are usually not severe and are typically analogous to a mild cold. However, in infants and toddlers the virus can cause lower respiratory tract infections including bronchiolitis or pneumonia with many of them requiring hospitalization. Nearly all children have been infected by age 3. There are known high-risk groups that infection with RSV is more likely to progress into the ALRI. Premature infants and/or infants suffering from lung or cardiac disease are at the highest risk to develop ALRI. Additional high-risk groups include the elderly, adults with chronic heart and/or lung disease, stem cell transplant patients and the immunosuppressed.

DETAILED DESCRIPTION OF THE INVENTION:
The compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds may also be administered as suppositories.

Read more:
https://www.patentguru.com/EP3687543B1



.

Enanta Pharmaceuticals files patent for 17ß-HSD13 inhibitors for treating metabolic disease - March 12

Enanta Pharmaceuticals. has filed a patent for compounds of Formula (I) as 17ß-HSD13 inhibitors for treating metabolic diseases** and liver conditions. The patent claim includes a compound represented by Formula I or its pharmaceutically acceptable salt or ester.

Furthermore, the patent application describes methods for preventing or treating 17ß-HSD13 mediated diseases or conditions in individuals by administering a therapeutically effective amount of the compound. The diseases or conditions targeted include nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver fibrosis, and hepatocellular carcinoma (HCC). The use of the compound in the manufacture of medicaments for these specific diseases is also claimed, emphasizing the potential therapeutic applications of the disclosed compound.

https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-files-patent-for-17-hsd13-inhibitors-for-treating-metabolic-disease/

**Metabolic disorders: Types, causes, and symptoms -
Examples of metabolic disorders include diabetes, Gaucher's disease, and hemochromatosis. Symptoms can include tiredness, weight loss or gain, and nausea and vomiting. Metabolism is a term that describes the biochemical processes that allow people to grow, reproduce, repair damage, and respond to their environment.

Thank you.

Is this how Amgen started out?

Everything you wanted to know about ENANTA's Patents -

Enanta Pharmaceuticals Patents – Key Insights and Stats
October 25, 2023

Enanta Pharmaceuticals has a total of 1607 patents globally, out of which 619 have been granted. Of these 1607 patents, more than 49% patents are active.

Read more:
https://insights.greyb.com/enanta-pharmaceuticals-patents/

I’m not saying that Hepludex infringes ENTA’s new HDV patent, but for the sake of discussion let’s assume that it does.

I see what you are saying.

Is this how Amgen started out? Was there a huge patent collection, but much difficulty in establishing collaborations and getting their products into the market? At nearly two decades Enanta must be getting close to their breakout, next Amgen.

I’m not saying that Hepludex infringes ENTA’s new HDV patent, but for the sake of discussion let’s assume that it does. Hepludex has had minimal sales to date (it’s not yet approved in the US), so almost all of the hypothetical upside from a patent lawsuit is still obtainable.

I'll have to echo that. The more I thought about that the more confused I got about it.
Surely the Gilead product has it's own patent/IP and I couldn't quite grasp how a new patent ....would *suplant* (in the sense of replace) be an appropriate word? Or would two patents in effect fighting it out to decide who gets the money mean a lawsuit?

Also, wouldn't having a product protected by an IP that made possible a HBV treatment (remains to be seen, of course) be a greater "win" as Enanta could conceivably become best in class, first highly effective to approval, with TWO patentable drugs owned by Enanta or coformulated so as to make it less possible for a competitor to use to test their in-the-works program? My simple take was the hope that the new compound/method would make that possible.
Perhaps I should have posted this in response to Dew's post instead of yours, but yours prompted me to also respond.

Ha! I was appreciative of Dew's post but was stopped while I pondered about how to reply. I hoped I'd be smarter the next day;
I'm not. : )

ENTA’s rationale for securing additional IP in HBV/HDV could be to seek royalties on GILD’s Hepludex rather than to support ENTA’s own HBV program.

Dew, could you explain how they could get royalties from patents they just filed?

Is this too much? Am I getting carried away or what??

Last current one - for now

December 2023 -

Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
Patent number: 11834436
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Type: Grant
Filed: April 13, 2021
Date of Patent: December 5, 2023
Assignee: Enanta Pharmaceuticals, Inc.

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or

In addendum:

Patent Assigned to Enanta Pharmaceuticals, Inc.

Spiropyrrolidine derived antiviral agents
Patent number: 11919910
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Type: Grant
Filed: November 9, 2022
Date of Patent: March 5, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Ruichao Shen, Xuechao Xing, Yong He, Matthew C. Rhodes, Yat Sun Or

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Read on -They're cornering the market!! Same page -

Spiropyrrolidine derived antiviral agents
Patent number: 11912714
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: November 9, 2022
Date of Patent: February 27, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Hui Cao, Wei Li, Xuri Gao, Jiajun Zhang, Xiaowen Peng, Jorden Kass, Ruichao Shen, Guoqiang Wang, Yat Sun Or

Benzodiazepine derivatives as RSV inhibitors
Patent number: 11912695
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: January 13, 2022
Date of Patent: February 27, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or

Functionalized heterocycles as antiviral agents
Patent number: 11891393
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: November 3, 2021
Date of Patent: February 6, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Joseph Panarese, Dexter Davis, Samuel Bartlett, Katherine Chong, Nathaniel Kenton, Yat Sun Or

Alkyne-containing antiviral agents
Patent number: 11858945
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: November 9, 2022
Date of Patent: January 2, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Joseph D. Panarese, Samuel Bartlett, Guoqiang Wang, Yat Sun Or

…I have almost stopped following the HBV space since the 514 asset seemed to have been shelved. ENTA’s rationale for securing additional IP in HBV/HDV could be to seek royalties on GILD’s Hepludex rather than to support ENTA’s own HBV program.

Background—HDV infection is essentially a subtype of HBV infection that comprises the most intractable cases. The most advanced programs for HDV are GILD’s Hepludex and VIR’s VIR-3434/VIR-2218 combination. Hepludex is approved in the EU but not in the US, where GILD received a CRL in 2022 (#msg-170307133); VIR’s combination is in phase-2.

The 3/6/24 Form-4 transactions were grants to the company's independent directors following the annual shareholders' meeting.

I was excited to see this too. To already own a good HBV asset is an advantage, but being able to select various in development compounds that might play well with that asset (EDP-514) and/or with a nuke, things could ramp up quickly. It brings to mind the Abbott/Abbvie collaboration where not once but twice the two companies were able to tailor complimentary compounds in the HCV space.

I'd venture that they already have a start or starts (various potential compounds) and hope we may soon get an update on when and whether to expect preclinical data or sense on how far away a trial could be.
I'll admit- I have almost stopped following the HBV space since the 514 asset seemed to have been shelved.

It also came to my mind that Jay Luly often refers to Enanta as a drug discovery company.
I'm wondering, if that were the case, (as it pertains to a certain PFE lawsuit) wouldn't it behoove you to have a solid branch of the company to protect those IP assets?

It would be windfall for investors if there was a settlement or win against Pfizer over Covid intellectual property this year.

Enanta Pharmaceuticals PATENTS new compounds for HBV and HDV - MARCH 9, 2024

Thanks Steve. So in the not so distant future, EDP-514 might get a new friend in the battle against HBV. I just checked the ENTA web site and there was nothing there yet about the new patents but I will keep monitoring.

Enanta Pharmaceuticals PATENTS new compounds for HBV and HDV - MARCH 9, 2024

Enanta Pharmaceuticals Inc. has disclosed new fused heterobicyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.

https://www.bioworld.com/topics/520-bioworld-science

The options in question did not expire until 2033, so this is a bullish signal. Thanks DEW.

Several insiders did the same on March 8, 2024. These options would have expired on March 6, 2034.
https://ir.enanta.com/static-files/e961f549-17bf-40f1-8310-7474cbd22802


My next post may be the BULLISH rationale.

I'm getting more excited about this area for ENTA if they can get a good compound. Liver tox is tough to predict preclinically (THLD acknowledged this), so the phase 1 next year is going to be quite meaningful (especially with a good biomarker of activity to go along w safety)

dewophile, thanks so much for that detailed analysis. I must admit I haven't done any real digging into Kit inhibitors. I expect a real roller coaster ride for ENTA as their Kit inhibitor enters and proceeds through trials.

[THRD] had 2 cases of DILI (drug induced liver injury) in their first 3 patients! They think they have identified the metabolite causing this and are hopeful. Ouch! I'm getting more excited about this area for ENTA if they can get a good compound. Liver tox is tough to predict preclinically (THLD acknowledged this), so the phase 1 next year is going to be quite meaningful (especially with a good biomarker of activity to go along w safety). If I were a baseball manager, I would say ENTA was overdue for a successful at-bat, LOL.

THRD had a presentation yesterday by the way. They reiterated a few things that ENTA mentioned:

1. the biology is very much mast cell mediated, and kit inhibitors are really the master regulators of mast cells. So all the other mechanisms may hit upstream or downstream, but you simply don't get the immediate inactivation of resident mast cells (followed by decrease in mast cells) with other mechanisms, so this is likely why you see such high efficacy
2. ENTA had mentioned that you can use a biomarker (tryptase) in phase 1, but THRD emphasized this point. They said there is now enough efficacy data in the indication linked to tryptase that the efficacy curves and tryptase curves "sit on top of one another". So it is a VERY good biomarker of efficacy that you can employ in phase 1. And you can drive tryptase levels down to undetectable levels with Kit inhibition
3. As for safety it (and efficacy) following the CLDX gives good insight, and it seems the more data there is the more reassuring the safety profile (e.g. the neutropenia and other on target effects don't seem to be that significant at all).
4. reiterated ENTA's take to a tee - that if you can get efficacy even close to an antibody for KIT w an oral drug it is a clearly attractive profile (they used psoriasis as a model where oral drugs are given first line most often even when efficacy is even lower than parenteral drugs/biologics)
5. They had 2 cases of DILI (drug induced liver injury) in their first 3 patients! They think they have identified the metabolite causing this and are hopeful. In total 5 patients were enrolled but they never made it past the lowest dose and even at that lowest dose they found significant tryptase inhibition
6. They mentioned they are still doing preclinical work on follow on compounds in addition to this second generation compound that should enter the clinic mid year. This tells me even they think there is room for better potency, selectivity, or both. Hopefully ENTA can come up with a compound that can compete or exceed because they will be at least 6-12 months behind (THLD ended up with a nearly 2 year delay when their first gen compound ran into liver issues)
7. The second indication they will be looking at is asthma. Even though plenty of biologics from GSK, REGN, etc., no new oral drugs for 25 or so years here. I don't need to tell you that would be a massive opportunity, but first things first!
I'm getting more excited about this area for ENTA if they can get a good compound. Liver tox is tough to predict preclinically (THLD acknowledged this), so the phase 1 next year is going to be quite meaningful (especially with a good biomarker of activity to go along w safety)

There is probably room for both. Assuming safety equivalent milder cases go for an easier to take oral agent more severe an injection. The sweet spot is obviously a more efficacious oral drug which is the opportunity enanta sees. Safety will be paramount the first oral kit drug for CSU was pulled for liver tox. That’s why phase 1 is actually going to be an important inflection point for this drug (along w the fact you can check bio markers to confirm target engagement even in healthy volunteers )